Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Profil von irwpresse_en

Blog
Battery X Metals Announces Confidential Submission of Draft Registration Statement with the U.S. Securities and Exchange Commission in Connection with Proposed U.S. National Securities Exchange Initial Public Offering
Battery X Metals Announces Confidential Submission of Draft Registration Statement with the U.S. Securities and Exchange Commission in Connection with Proposed U.S. National Securities Exchange Initial Public Offering

VANCOUVER, British Columbia – December 12, 2025 – Battery X Metals Inc. (CSE:BATX) (OTCQB:BATXF) (FSE:5YW0, WKN:A41RJF) (“Battery X Metals” or the “Company”) an energy transition resource

Gold Royalty Completes Pedra Branca Royalty Acquisition
Gold Royalty Completes Pedra Branca Royalty Acquisition

Vancouver, British Columbia – December 12, 2025 Gold Royalty Corp. (“Gold Royalty” or the “Company” - https://www.commodity-tv.com/ondemand/companies/profil/gold-royalty-corp/) (NYSE

Pasinex Receives MAPEG Approval for Horzum AS; Announces 1,000-Metre Development Plan for Pinargözü Mine
Pasinex Receives MAPEG Approval for Horzum AS; Announces 1,000-Metre Development Plan for Pinargözü Mine

TORONTO, ON – December 12, 2025 – Pasinex Resources Limited (CSE: PSE; FSE: PNX) (“Pasinex” or the “Company”) is pleased to announce that Türkiye’s General Directorate of Mining and Petroleum

GreenX Completes Acquisition of the Tannenberg Copper Project: https://www.irw-press.at/prcom/images/messages/2025/82180/GreenX_121225_ENPRcom.001.jpeg
GreenX Completes Acquisition of the Tannenberg Copper Project

12 DECEMBER 2025. GreenX Metals Limited (ASX:GRX, LSE:GRX, GPW:GRX, Germany-FSE:5PMA) (GreenX or Company) is pleased to announce that further to its announcement on 20 November 2025,

Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants
Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants

Vaccine Was Safe and Well Tolerated at the Maximum Tolerated Dose

 

Results Support Advancement of the Program into Phase 2 Development

 

Combination of Keytruda® and the vaccine generated T